Anthem Biosciences Ltd.

•

anthembio.comBSE: 544449NSE: ANTHEM

Market Cap₹ 53,098 Cr.

Current Price

High / Low₹ 978 / 579

Stock P/E92.2

Book Value₹ 56

Price to Book12.25

Dividend Yield0.21 %

ROCE29.6 %

ROE22.0 %

Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Contract Manufacturing Development & Discovery Services (CRDMO ): 83.4% • Speciality Ingredients: 16.6%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Company has a healthy return on capital (ROCE) of 27.5%
Company has a good return on equity (ROE) track record: 3 Years ROE 21.0%
Company has consistently been profitable over the last 5 years
Company comfortably covers its interest (117.8x coverage)
Institutional investors have been accumulating - FII+DII up 11.0pp

CONS

Promoter holding has decreased over last 2 years: -12.6pp
Receivables are growing faster than sales - a possible quality concern
Stock is trading at 12.3x its book value
Operating margins have contracted to 38.2% from 48.1%
Expensive relative to growth - PEG of 6.0

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTYLARGEMIDCAP250 NIFTYMIDCAP150 NIFTY MIDCAP 150 NIFTY TOTAL MKT NIFTY 500

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	ANTHEM	942.25	92.19	53098.43	0.21	119.94	-11.67	418.22	-22.58	29.62	36.00

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	339	525	498	483	540	550	423	611	418
	218	330	338	288	349	332	266	344	299
Operating Profit	121	195	160	195	191	218	157	267	120
OPM %	35.71%	37.19%	32.04%	40.40%	35.45%	39.62%	37.15%	43.74%	28.62%
	19	28	24	14	23	48	8	52	25
Interest	4	4	3	1	2	3	0	2	1
Depreciation	19	20	20	30	26	34	35	40	30
Profit before Tax	118	200	161	178	186	230	130	278	145
Tax %	30.17%	18.85%	22.80%	53.66%	27.09%	24.46%	28.86%	31.72%	17.04%
Net Profit	0	0	0	0	136	173	93	190	120
	1.47	2.90	2.22	1.48	2.43	3.09	1.65	3.38	2.13

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	248	308	356	633	1,103	1,231	1,057	1,419	1,845	2,124	2,002
	178	215	248	451	696	664	634	914	1,174	1,290	1,240
Operating Profit	70	94	108	182	408	567	423	505	671	834	762
OPM %	28.32%	30.37%	30.40%	28.75%	36.96%	46.06%	40.01%	35.59%	36.38%	39.26%	38.06%
	3	5	7	21	37	49	147	64	86	131	133
Interest	6	5	5	20	17	12	9	10	11	7	6
Depreciation	10	21	22	62	62	58	64	82	89	134	138
Profit before Tax	58	73	88	121	366	546	497	477	657	824	783
Tax %	32.47%	31.13%	25.04%	23.18%	25.79%	25.74%	22.54%	23.05%	31.30%	28.20%	26.40%
Net Profit	39	50	66	93	271	406	385	367	451	592	576
EPS	46.07	37.18	78.86	108.00	323.41	7.11	6.75	6.57	8.07	10.54	—
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.98%	—

COMPOUNDED SALES GROWTH

10 Years:: 32%
5 Years:: 14%
3 Years:: 26%

COMPOUNDED PROFIT GROWTH

10 Years:: 43%
5 Years:: 17%
3 Years:: 15%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: 15%

RETURN ON EQUITY

10 Years:: 33%
5 Years:: 25%
3 Years:: 21%
Last Year:: 22%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	8	8	8	8	8	9	114	112	112	112
	89	138	213	413	693	1,346	1,627	1,813	2,264	2,897
	79	120	191	136	120	62	133	249	107	49
Trade Payables	24	26	33	58	77	65	72	101	110	75
	35	64	65	159	192	244	159	202	356	473
Total Liabilities	235	355	510	776	1,091	1,726	2,105	2,477	2,949	3,606
	91	86	258	306	361	329	449	483	705	783
Capital Work in Progress	22	74	43	50	19	154	164	345	297	264
	2	8	27	99	209	273	499	472	433	1,007
	37	47	58	125	35	58	129	211	340	125
	0	0	0	0	0	0	0	490	450	591
Cash & Bank	2	4	11	22	41	349	343	184	172	275
	81	136	113	174	426	563	520	292	550	561
Total Assets	235	355	510	776	1,091	1,726	2,105	2,477	2,949	3,606

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	211	349	456	421	140	271	844
Cash from Investing	-109	-196	-205	-376	-221	-147	-702
Cash from Financing	-48	-63	181	64	-77	-136	-40
	9	18	308	-6	-158	-12	103

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Jul 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	84.00	82.96	76.85	76.84	74.69	74.69	74.69	74.68	71.42
	0.00	0.00	0.00	0.00	1.50	1.66	1.37	1.28	2.57
	0.00	0.00	0.00	0.00	3.59	7.21	7.60	11.55	13.48
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	16.00	17.04	23.15	23.16	20.22	16.42	16.35	12.49	12.53

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08

Updates

2026-09-08 - Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '.

2026-07-27

Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-27 - Anthem Biosciences Limited has informed the Exchange about Transcript

2026-07-24

Shareholders meeting

2026-07-24 - Anthem Biosciences Limited has submitted the Exchange the voting results and a copy Srutinizers report of the 20th Annual General Meeting held on July 22, 2026.

2026-07-22

Shareholders meeting

2026-07-22 - Anthem Biosciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 22, 2026

2026-07-22

Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-22 - Anthem Biosciences Limited has informed the Exchange about Link of Recording

2026-07-22

Copy of Newspaper Publication

2026-07-22 - Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-21

Press Release (Revised)

2026-07-21 - Anthem Biosciences Limited has informed the Exchange regarding a revised press release dated July 21, 2026, titled "Press Release on Unaudited Financial Results for the Quarter ended June 30, 2026".

2026-07-21

Investor Presentation

2026-07-21 - Anthem Biosciences Limited has informed the Exchange about Investor Presentation

2026-07-21

Press Release

2026-07-21 - Anthem Biosciences Limited has informed the Exchange regarding a press release dated July 21, 2026, titled "Press Release on the Unaudited Financial Results for the quarter ended June 30, 2026".

News

Recent coverage and analyst commentary for ANTHEM

Loading news…

🤖

AI Stock Analyst

Anthem Biosciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

ANTHEM

942.25

92.19

53098.43

0.21

119.94

-11.67

418.22

-22.58

29.62

36.00

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

339

525

498

483

540

550

423

611

418

218

330

338

288

349

332

266

344

299

Operating Profit

121

195

160

195

191

218

157

267

120

OPM %

35.71%

37.19%

32.04%

40.40%

35.45%

39.62%

37.15%

43.74%

28.62%

Interest

Depreciation

Profit before Tax

118

200

161

178

186

230

130

278

145

Tax %

30.17%

18.85%

22.80%

53.66%

27.09%

24.46%

28.86%

31.72%

17.04%

Net Profit

136

173

190

120

1.47

2.90

2.22

1.48

2.43

3.09

1.65

3.38

2.13

Mar 2015

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

248

308

356

633

1,103

1,231

1,057

1,419

1,845

2,124

2,002

178

215

248

451

696

664

634

914

1,174

1,290

1,240

Operating Profit

108

182

408

567

423

505

671

834

762

OPM %

28.32%

30.37%

30.40%

28.75%

36.96%

46.06%

40.01%

35.59%

36.38%

39.26%

38.06%

147

131

133

Interest

Depreciation

134

138

Profit before Tax

121

366

546

497

477

657

824

783

Tax %

32.47%

31.13%

25.04%

23.18%

25.79%

25.74%

22.54%

23.05%

31.30%

28.20%

26.40%

Net Profit

271

406

385

367

451

592

576

EPS

46.07

37.18

78.86

108.00

323.41

7.11

6.75

6.57

8.07

10.54

—

Dividend Payout %

0.00%

18.98%

—

Mar 2015

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

114

112

138

213

413

693

1,346

1,627

1,813

2,264

2,897

120

191

136

120

133

249

107

Trade Payables

101

110

159

192

244

159

202

356

473

Total Liabilities

235

355

510

776

1,091

1,726

2,105

2,477

2,949

3,606

258

306

361

329

449

483

705

783

Capital Work in Progress

154

164

345

297

264

209

273

499

472

433

1,007

125

129

211

340

125

490

450

591

Cash & Bank

349

343

184

172

275

136

113

174

426

563

520

292

550

561

Total Assets

235

355

510

776

1,091

1,726

2,105

2,477

2,949

3,606

Mar 2015

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

211

349

456

421

140

271

844

Cash from Investing

-109

-196

-205

-376

-221

-147

-702

Cash from Financing

-48

-63

181

-77

-136

-40

308

-6

-158

-12

103

Mar 2015

Mar 2016

Mar 2017

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Jul 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

84.00

82.96

76.85

76.84

74.69

74.68

71.42

0.00

1.50

1.66

1.37

1.28

2.57

0.00

3.59

7.21

7.60

11.55

13.48

Government

0.00

16.00

17.04

23.15

23.16

20.22

16.42

16.35

12.49

12.53

Anthem Biosciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Anthem Biosciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI